Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
761-780 of 1,307 trials

Knee Osteoarthritis: Intra-Articular Clodronate Study

We are investigating whether different doses of clodronate can help reduce knee pain and improve function in people with painful knee osteoarthritis. The study will also monitor safety and tolerability of the treatment.

Knee Osteoarthritis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesOrthopedics and TraumatologyRheumatology

Heart Procedure: Protamine Use in Aortic Valve Replacement

We are studying whether protamine can help reduce major bleeding and ischemic events in patients after transcatheter aortic valve replacement. This trial also examines other safety factors and complications related to the procedure.

Transcatheter Aortic Valve Replacement (TAVR)>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dornase Alfa for Severe Trauma Patients in ICU

We are studying whether inhaled dornase alfa can help reduce serious lung complications in ventilated patients with severe trauma. This trial aims to see if it lowers the risk of ARDS and improves recovery outcomes.

Severe TraumaConfirmation phase (III)Standard MedicinesInternal MedicinePulmonology

Gentamicin Injection for Cat Scratch Disease Lymphadenitis

We are studying whether an injection of gentamicin can improve symptoms in patients with cat scratch disease lymphadenitis compared to a placebo. This trial also looks at pain relief and lymph node changes over time.

Bartonellosis≤3 monthsConfirmation phase (III)≤5 visitsStandard MedicinesInfectious DiseasesInternal Medicine

Inhaled Molgramostim for Pediatric Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

We are studying the effects of inhaled molgramostim in children and teens with aPAP. The goal is to see if it is safe and effective for improving their condition.

Pulmonary Alveolar Proteinosis1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPediatricsPulmonology

Cancer Imaging: [18F]AlF-FAPI-74 PET/CT

We are studying a new imaging method for patients with newly diagnosed esophagogastric and pancreatic cancers. This trial aims to see if it detects cancer better than current imaging techniques.

Pancreatic CancerEsophagogastric AdenocarcinomaGastric Cancer1-2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Glucothera Plus for Children on Peritoneal Dialysis

We are studying the safety of Glucothera Plus in children receiving peritoneal dialysis. We also want to see if it helps restore L-carnitine levels in these patients.

End-stage Kidney Disease6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyPediatrics

Colchicine for Peripheral Artery Disease

We are studying whether a low dose of colchicine can help reduce serious heart and limb problems in patients with peripheral artery disease. This research aims to improve safety and outcomes for those affected.

Peripheral Arterial Disease>2 yearsConfirmation phase (III)Investigational MedicinesCardiology

Pain Management After Colorectal Surgery: Continuous Wound Infusion Study

We are investigating whether continuous infusion of local pain relief helps patients recover better after minimally invasive colorectal surgery. The study compares this method to a placebo to see its effects on pain and recovery time.

Recovery After Colorectal Surgery1-2 yearsConfirmation phase (III)Standard MedicinesGastroenterologyInternal MedicineOtolaryngology

Severe Asthma: Tezepelumab Medication Study

We are studying if tezepelumab can help patients aged 12 to 80 with severe asthma reduce their daily medication while keeping their symptoms under control.

Severe Asthma1-2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePulmonology

Generalized Myasthenia Gravis: Telitacicept Study

We are testing a new treatment called telitacicept for people with generalized myasthenia gravis. The study aims to see if it works better than a placebo and to check its safety.

Generalized Myasthenia Gravis6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurologyRheumatology

Advanced Non-Small Cell Lung Cancer: PD-1 Inhibitor with Chemotherapy and Radiation

We are studying whether adding radiation to a PD-1 inhibitor and chemotherapy improves survival and tumor response in patients with advanced non-small cell lung cancer. This trial also looks at side effects and quality of life.

Advanced Non-Small Cell Lung Cancer (NSCLC)3-6 monthsConfirmation phase (III)No PlaceboStandard MedicinesOncology

Metastatic Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether adding chemotherapy after surgery or ablation helps improve outcomes for patients with metastatic colorectal cancer compared to just follow-up care.

Metastatic Colorectal CancerConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Bladder Cancer: Nadofaragene Firadenovec Treatment

We are studying the safety and effectiveness of nadofaragene firadenovec, given alone or with chemotherapy or immunotherapy, for adults with non-muscle invasive bladder cancer that hasn't responded to BCG therapy.

High-risk Non-Muscle-Invasive Bladder Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Ependymoma Treatment: SIOP Ependymoma II Program

We are exploring new chemotherapy options and surgical techniques for children and young adults with ependymoma. Our goal is to improve survival rates and treatment effectiveness compared to standard methods.

Ependymoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Primary Hyperoxaluria: DCR-PHXC Injection Study

We are evaluating a new injection for patients with Primary Hyperoxaluria to see how it affects kidney function and overall safety. The study also looks at its impact on kidney stones and quality of life.

Primary Hyperoxaluria>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyNephrology

Triple Negative Breast Cancer: Sacituzumab Govitecan and Pembrolizumab Study

We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.

Triple Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Relapsing Multiple Sclerosis: CYB704 vs. Ocrevus

We are comparing a new biosimilar treatment to Ocrevus for people with relapsing multiple sclerosis. The study aims to evaluate how well it works and its safety profile.

Multiple Sclerosis Relapse>2 yearsConfirmation phase (III)Neurology

Elderly Primary CNS Lymphoma: High-Dose Chemotherapy Study

We are comparing a high-dose chemotherapy followed by stem cell transplantation to standard chemotherapy for elderly patients with primary CNS lymphoma. The goal is to see which treatment leads to better survival and quality of life.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology